Plan pharma facility construction with a Gantt chart. Covers FDA CGMP phases, IQ/OQ/PQ qualification, process validation, and PAI milestones.
Pharmaceutical manufacturing facility construction is not simply a construction project -- it is a regulatory compliance project that happens to involve construction. The U.S. Food and Drug Administration's Current Good Manufacturing Practice (CGMP) regulations under 21 CFR Part 211 govern every design decision, every installation choice, and every operational procedure in a pharmaceutical plant. A construction schedule that does not account for the qualification and validation phases required before FDA approval will inevitably slip, often by years.
A Gantt chart for pharmaceutical plant construction must model the full lifecycle: from product definition through regulatory strategy, design, construction, commissioning, qualification, process validation, pre-approval inspection, and commercial production. Each phase has regulatory touchpoints that are not optional. Skipping or shortcutting any of them creates rework -- and rework in a pharma facility can set a project back 12-24 months.
The core difference is that a pharmaceutical manufacturing facility must be proven to consistently produce product that meets its specifications before it can be used for commercial manufacturing. This proof requires documented qualification of every system and validated manufacturing processes. The regulators review the documentation, and if it is inadequate, they will not approve the product made in that facility.
This requirement shapes the entire construction schedule. Commissioning -- verifying that systems are installed and functioning as designed -- must be completed before qualification can begin. Qualification generates the documented evidence that regulatory reviewers evaluate. Process validation follows qualification. The FDA Pre-Approval Inspection (PAI) follows process validation. Only then can commercial production begin.
The timeline from construction start to first commercial batch is typically three to five years for a new facility. For biologics, it is often longer.
Before the facility can be designed, the manufacturing process must be sufficiently defined. What will be manufactured -- API synthesis, drug product formulation, biologics (monoclonal antibodies, vaccines), sterile fill-finish -- determines the facility type, equipment requirements, and CGMP design standards.
For biologics: bioreactors, fermenters, and downstream purification equipment (centrifuges, chromatography columns, ultrafiltration/diafiltration) are required. The process uses living cells and requires containment and bioburden control throughout.
For sterile fill-finish: the fill line, lyophilizer (freeze dryer), and capping equipment require ISO Class 5 (Grade A) aseptic zones for filling operations, supported by ISO Class 7 and 8 support zones.
For small molecule oral solid dosage: granulation, blending, compression, and coating equipment in a non-sterile but CGMP-compliant environment.
Key milestones: Process description complete, equipment list defined, facility type confirmed.
The regulatory strategy determines which markets the product will be sold in and which agencies must approve both the product and the facility. For the U.S.: FDA CGMP qualification and, for new drugs, a Pre-Approval Inspection before the NDA or BLA is approved. For the EU: EMA and member state inspections. For other markets: local health authority requirements.
The regulatory strategy affects the facility design standards, the documentation requirements for qualification, and the timeline to first approval.
Key milestones: Regulatory strategy approved, target inspection timeline established.
The User Requirements Specification (URS) defines what the facility and each system must do. It is the foundation of the qualification program -- everything in the IQ, OQ, and PQ protocols traces back to a URS requirement.
Design Qualification (DQ) documents that the design meets the URS requirements. It is reviewed and approved before construction begins. A facility that skips DQ will spend significant time during later qualification stages discovering design gaps that require expensive changes.
Key milestones: URS approved, DQ complete and approved.
Front-End Engineering and Design (FEED) develops the process design, equipment specifications, and facility layout to sufficient detail to support procurement and construction. CGMP design requirements are embedded throughout: separate areas for different products to prevent cross-contamination, dedicated HVAC with HEPA filtration and pressure differentials between zones, material and personnel airlocks, separate drain systems, gowning areas with defined entry/exit sequences.
Detailed engineering converts the FEED design into construction-ready drawings and specifications. For a sterile facility, the level of detail required for the HVAC, clean utilities, and cleanroom construction is extremely high.
Key milestones: FEED complete, design freeze for major systems, construction documents issued.
Long-lead items must be ordered during or immediately after FEED. For biologics facilities: bioreactors (12-18 months lead time for large stainless steel vessels), lyophilizers for sterile product (9-15 months), HVAC equipment (6-12 months for custom air handling units). For clean utilities: Water for Injection (WFI) systems (9-12 months), Clean Steam generators (6-9 months), and Pure Steam systems.
Key milestones: Bioreactor PO issued, lyophilizer PO issued, HVAC equipment ordered, clean utility equipment ordered.
Construction of a pharmaceutical facility requires specialized contractors familiar with CGMP environments. Cleanroom construction uses surfaces that can be cleaned and sanitized: epoxy or resin floors, coved bases that eliminate hard-to-clean corners, smooth seamless wall and ceiling systems, and surfaces that withstand repeated cleaning with harsh disinfectants.
HVAC installation is a specialty: pressure relationships between every room must be maintained precisely (cleanrooms are positive pressure; containment areas are negative pressure), and HEPA filter banks must be installed to prevent bypass leakage.
Key milestones: Building enclosed, clean room construction complete, major equipment installed.
Commissioning verifies that installed systems function as designed. In a pharmaceutical facility, commissioning is the transition step between construction and qualification. The HVAC systems are balanced and tested. The WFI system is sterilized and validated for bacterial endotoxin levels. The clean steam system is tested. Equipment is mechanically checked.
Commissioning generates records that feed into the qualification documentation.
Key milestones: HVAC commissioning complete, clean utilities commissioned, major equipment commissioned.
Installation Qualification (IQ): Documents that equipment and systems are installed correctly and match the approved design and supplier specifications.
Operational Qualification (OQ): Demonstrates that equipment and systems operate correctly across their intended operating ranges. This includes challenge testing of HVAC pressure differentials, HEPA filter integrity testing (DOP/PAO testing), clean utility quality testing, and equipment functional testing.
Performance Qualification (PQ): Demonstrates that the system consistently performs as intended under actual or simulated production conditions.
Each qualification protocol must be written, approved, executed, and the resulting report approved before the next phase can begin.
Key milestones: IQ complete, OQ complete, PQ complete.
Process validation demonstrates that a manufacturing process consistently produces product meeting its specifications. FDA requires at least three consecutive validation batches at the intended commercial scale. For biologics, this means three full bioreactor runs through the entire downstream process -- each run may take 2-4 weeks of manufacturing time plus weeks of analytical testing.
Key milestones: Validation protocol approved, first validation batch complete, three consecutive validation batches complete.
The FDA conducts a Pre-Approval Inspection of the facility to verify CGMP compliance before approving the NDA or BLA. The inspection team reviews qualification records, batch records, SOPs, training records, laboratory systems, and the physical facility. Deficiencies issued at the PAI (Form 483 observations) must be remediated before approval is granted.
Key milestones: PAI notification received, PAI conducted, 483 responses submitted, approval received.
With approval in hand, commercial production begins. The facility is now operating under ongoing FDA oversight: periodic surveillance inspections, annual product reviews, CGMP continuous compliance requirements.
The critical insight for Gantt chart construction in a pharma project is that qualification cannot compress. IQ protocols must be executed; OQ challenges must run; validation batches must be manufactured and tested. Unlike construction phases that can be accelerated by adding resources, qualification takes the time it takes.
The schedule should be built backward from the target approval date, with the qualification and validation phases anchored first, then construction and procurement dates derived from those anchors. Long-lead procurement is then the first procurement action required.
Gantt-chart.io makes it straightforward to build this backward-from-target-date schedule, link dependencies across phases, and track progress against the regulatory milestones that matter most.